---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000003"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:29:39.057331+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine and Voyager form $175M upfront gene therapy collaboration for GBA1 and rare CNS targets

## Summary
- $175M upfront: ~$136M cash to Voyager plus $39M equity at $8.88/share (50% premium to 30-day VWAP).
- Up to $1.5B in development milestones (GBA1 ≤$985M; each of three new CNS programs ≤$175M) plus commercial milestones & royalties.
- Voyager can opt for 50/50 US co-dev/co-commercial on GBA1 after Phase 1 data; otherwise tiered royalties (low-double-digit to 20% US).
- Three new rare CNS gene therapy programs leverage Voyager's TRACER capsids; Neurocrine funds all development costs.
- Jude Onyia, Ph.D. (Neurocrine CSO), to join Voyager's board effective closing.

## SEC filing metadata
- accession: 0000914475-23-000003
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/0000914475-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/nbix-20230108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000003
- JSON: https://secwatch.observer/filing/0000914475-23-000003.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000003.txt

## Key facts
- Material Agreements
  NEUROCRINE BIOSCIENCES INC entered into Collaboration and License Agreement with Voyager Therapeutics, Inc. valued at approximately $136.0 million (effective 2023-01-08).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Voyager Therapeutics, Inc.
  - Value: approximately $136.0 million
  - Effective: 2023-01-08
  source text: On January 8, 2023 (the “Agreement Date”), Neurocrine Biosciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Voyager Therapeutics, Inc. (“Voyager”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/0000914475-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.